(Q40433878)

20 September 2017

1 reference

title

Long-acting inhaled beta agonists (English)

1 reference

20 September 2017

Long-Acting Inhaled Beta Agonists (English)

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

31 May 2024

author name string

S. A. Tilles

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7592242

31 May 2024

H. S. Nelson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7592242

31 May 2024

language of work or name

English

0 references

publication date

1 January 1995

1 reference

full work available at URL

20 September 2017

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

31 May 2024

1 reference

20 September 2017

volume

32

1 reference

20 September 2017

issue

6

1 reference

20 September 2017

page(s)

397-404

1 reference

Regular inhaled beta-agonist treatment in bronchial asthma.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

The use of beta-agonists and the risk of death and near death from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Basic pharmacology of new long-acting sympathomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Long- versus short-acting beta 2-agonists. Implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Long-term studies on long-acting sympathomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Long-term efficacy of formoterol compared to salbutamol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Prevention of exercise induced asthma by inhaled salmeterol xinafoate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Paradoxical bronchospasm associated with the use of inhaled beta agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Twelve months, treatment with inhaled salmeterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02770909409077750

Regular Inhaled Beta-Adrenergic Agonists in the Treatment of Bronchial Asthma: Beneficial or Detrimental?

21 January 2018

5

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Fenoterol and Death from Asthma in New Zealand

31 May 2024

6

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma

31 May 2024

11

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

31 May 2024

15

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

31 May 2024

17

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

31 May 2024

18

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease

31 May 2024

21

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

31 May 2024

22

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis

31 May 2024

26

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma

31 May 2024

28

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Prolonged Protection against Methacholine-induced Bronchoconstriction by the Inhaled β2-Agonist Formoterol

31 May 2024

30

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Protection against allergen-induced asthma by salmeterol

31 May 2024

31

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses

31 May 2024

32

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

31 May 2024

33

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children

31 May 2024

35

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma

31 May 2024

36

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol

31 May 2024

39

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Results of prescription event monitoring study of salmeterol

31 May 2024

45

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency

31 May 2024

46

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

31 May 2024

48

1 reference

https://api.crossref.org/works/10.3109/02770909409077750

31 May 2024

Identifiers

1 reference

20 September 2017

1 reference